Effects of smoking status and schizotypy on latent inhibition

Journal of Psychopharmacology

Volumn 13, Issue 1, 1999, Pages 45-57

  Della Casa, V ^a   Hofer I ^a   Weiner, I ^b   Feldon, Joram ^a  

^a ETH ZURICH   (Switzerland)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Attention; Latent inhibition; Negative priming; Nicotine; Physiology; Schizophrenia; Schizotypy; Smoking; Stroop effect

Indexed keywords

ADULT; ARTICLE; AUDITORY STIMULATION; COGNITION; FEMALE; HUMAN; HUMAN EXPERIMENT; INFORMATION; LATENT INHIBITION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; TASK PERFORMANCE; VISUAL STIMULATION;

EID: 0344959461     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119901300106     Document Type: Article

References (95)

1. Allan L M, Williams J H, Wellman N A, Tonin J, Taylor E, Feldon J, Rawlins J N P (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Person Individ Diff 19: 893-902
2. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders. American Psychiatric Association Press, Washington, DC
3. Baruch I, Hemsley D R, Gray J A (1988a) Differential performance of acute and chronic schizophrenics in latent inhibition task. J Nerv Ment Dis 176: 598-606
4. Baruch I, Hemsley D R, Gray J A (1988b) Latent inhibition and 'psychotic proneness' in normal subjects. Person Individ Diff 9: 777-783
5. Beech A, Claridge G (1987) Individual differences in negative priming: relations with schizotypal personality traits. Br J Psychol 78: 349-356
6. Beech A, Baylis G C, Smithson P, Claridge G (1989) Individual differences in schizotypy as reflected in measures of cognitive inhibition. Br J Clin Psychol 28: 117-129
7. Beech A, McManus D, Baylis G, Tipper S, Agar K (1991) Individual differences in cognitive processes: towards an explanation of schizophrenic symptomatology. Br J Psychol 82: 417-426
8. Bentall R P, Claridge G S, Slade P D (1989) The multidimensional nature of schizotypal traits: a factor analytic study with normal subjects. Br J Clin Psychol 28: 363-375
9. Bullen J G, Hemsley D R, Dixon N F (1987) Inhibition, unusual perceptual experiences and psychoticism. Person Individ Diff 8: 687-691
10. Carter C S, Robertson L C, Nordahl T E (1992) Abnormal processing of irrelevant information in chronic schizophrenia: selective enhancement of Stroop facilitation. Psychiatry Res 41: 137-146
11. Chapman L J, Chapman J P, Raulin M L (1976) Scales for physical and social anhedonia. J Abnorm Psychol 85: 374-382
12. Chapman L J, Chapman J P, Raulin M L (1978) Body-image aberration in schizophrenia. J Abnorm Psychol 87: 399-407
13. Chapman L J, Chapman J P, Kwapil T R, Eckblad M, Zinser M C (1994) Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 103: 171-183
14. Christison G W, Atwater G E, Dunn L A, Kilts C D (1988) Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biol Psychiatry 23: 746-749
15. Claridge G, Broks P (1984) Schizotypy and hemisphere function. I. Theoretical considerations and the measurement of schizotypy. Person Individ Diff 5: 633-648
16. Claridge G S (1985) The origins of mental illness. Blackwell, Oxford
17. De La Casa L G, Lubow R E (1994) Memory for attended and nominally nonattended stimuli in low and high psychotic-prone normal subjects: The effects of test-anticipation. Person Individ Diff 17: 783-789
18. De La Casa L G, Ruiz G (1993) Latent inhibition and recall/recognition of irrelevant stimuli as a function of preexposure duration in high and low psychotic-prone normal subjects. Br J Psychol 84: 119-132
19. De La Casa L G, Ruiz G, Lubow R E (1993) Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: implications for schizophrenia. Biol Psychiatry 33: 707-711
20. Dunn L, Atwater G, Christison G, Kilts C (1989) Latent inhibition as an animal model of antipsychotic drug action. Soc Neurosci Abstr 15: 269
21. Erlenmeyer-Kimling L, Cornblatt B A (1992) A summary of attentional findings in the New York High Risk Project. J Psychiatr Res 26: 405-426
22. Eysenck H J, Eysenck S B G (1975) Manual of the Eysenck personality questionnaire. Hodder and Stoughton, London
23. Feldon J, Weiner I (1991a) An animal model of attention deficit. In Boulton A A, Baker G B, Martin-Iverson M T (eds), Neuromethods, Vol. 18: Animal models in psychiatry, pp. 313-361. Humana Press, Clifton, NJ
24. Feldon J, Weiner I (1991b) The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29: 635-646
25. Feldon J, Weiner I (1992) From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 26: 345-366
26. Fox E (1995) Negative priming from ignored distractors in visual selection: a review. Psychonom Bull Rev 2: 145-173
27. Franke P, Maier W, Hardt J, Hain C, Cornblatt B A (1994) Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings, and normal control subjects. Psychiatry Res 54: 259-272
28. Ginton A, Urca G, Lubow R E (1975) The effects of preexposure to a nonattended stimulus on subsequent learning: latent inhibition in adults. Bull Psychonom Soc 5: 5-8
29. Gottesman I, Shields J (1982) Schizophrenia: The epigenetic puzzle. Cambridge University Press, New York
30. Gray J A, Feldon J, Rawlins J N P, Hemsley D R, Smith A D (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14: 1-84
31. Gray N S, Hemsley D R, Gray J A (1992a) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiat Brain Res 1: 83-89
32. Gray N S, Pickering A D, Hemsley D R, Dawling S, Gray J A (1992b) Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107: 425-430
33. Gray J A, Mitchell S N, Joseph M H, Grigoryan G A, Dawe S, Hodges H (1994) Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine. Drug Dev Res 31: 3-17
34. Gray N S, Pilowsky L S, Gray J A, Kerwin R W (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine d2 binding using SPET. Schizophr Res 17: 95-107
35. Gruzelier J, Richardson A (1994) Patterns of cognitive asymmetry and psychosis proneness. Int J Psychophysiol 18: 217-225
36. Gruzelier J H (1996) The factorial structure of schizotypy: part I. Affinities with syndromes of schizophrenia. Schizophr Bull 22: 611-620
37. Hasenfratz M, Bättig K (1992) Action profiles of smoking and caffeine: Stroop effect, EEG, and peripheral physiology. Pharmacol Biochem Behav 42: 155-161
38. Hasenfratz M, Bättig K (1994) Pretask smoking and smoking during a task: effects on cognitive performance, puffing behavior, physiological and subjective parameters. Hum Psychopharmacol 9: 181-189
39. Jacober A, Hasenfratz M, Bättig K (1993) A nicotine dependent and a nicotine independent component of smoking related pulse and activity variation. Hum Psychopharmacol 8: 125-132
40. Joseph M H, Peters S L, Gray J A (1993) Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology 110: 187-192
41. Kalbfleisch J D, Prentice R L (1980) The statistical analysis of failure time data. John Wiley, New York
42. Killcross A S, Robbins T W (1993) Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 106: 1-11
43. Killcross A S, Dickinson A, Robbins T W (1994a) Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology 115: 185-195
44. Killcross A S, Dickinson A, Robbins T W (1994b) Effects of the neuroleptic a-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 115: 196-205
45. Kwapil T R, Miller M B, Zinser M C, Chapman J, Chapman L J (1997) Magical ideation and social anhedonia as predictors of psychosis proneness: a partial replication. J Abnorm Psychol 106: 491-495
46. Lee E T (1992) Statistical methods for survival data analysis. John Wiley, New York
47. Lenzenweger M F, Cornblatt B A, Putnick M (1991) Schizotypy and sustained attention. J Abnorm Psychol 100: 84-89
48. Lipp O V, Vaitl D (1992) Latent inhibition in human pavlovian differential conditioning: effect of additional stimulation after preexposure and relation to schizotypal traits. Person Individ Diff 13: 1003-1012
49. Lipp O V, Siddle D T, Arnold S L (1994) Psychosis proneness in a non-clinical sample II: a multi-experimental study of 'attentional malfunctioning'. Person Individ Diff 17: 405-424
50. Lubow R E (1973) Latent inhibition. Psychol Bull 79: 398-407
51. Lubow R E (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, New York
52. Lubow R E, Gewirtz J C (1995) Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull 117: 87-103
53. Lubow R E, Feldon J, Weiner I (1982) An animal model of attention. In Spiegelstein M Y, Levy A (eds), Behavioral models and the analysis of drug action, pp. 89-107. Elsevier, Amsterdam
54. Lubow R E, Weiner I, Schlossberg A, Baruch I (1987) Latent inhibition and schizophrenia. Bull Psychon Soc 25: 464-467
55. Lubow R E, Ingberg-Sacks Y, Zalstein-Orda N, Gewirtz J C (1992) Latent inhibition in low and high 'psychotic-prone' normal subjects. Person Individ Diff 13: 563-572
56. MacLeod C M (1991) Half a century of research on the Stroop effect: an integrative review. Psychol Bull 109: 163-203
57. Mednick S A, Schulsinger F (1968) Some premorbid characteristics related to breakdown in children with schizophrenic mothers. In Rosenthal D, Kety S S (eds), The transmission of schizophrenia, pp. 267-298. Pergamon, London
58. Meehl P E (1962) Schizotaxia, schizotypy, schizophrenia. Am Psychol 17: 827-838
59. Neill W T, Valdes L A, Terry K M (1995) Selective attention and the inhibitory control of cognition. In Dempster F N, Brainerd C J (eds), Interference and inhibition in cognition, pp. 207-261. Academic Press, San Diego
60. Nuechterlein K H, Dawson M E (1984a) Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 10: 160-203
61. Nuechterlein K H, Dawson M E (1984b) Vulnerability and stress factors in the developmental course of schizophrenia disorders. Schizophr Bull 10: 158-159
62. Perkins K A, Epstein L H, Stiller R L, Marks B L, Jacob R G (1989) Chronic and acute tolerance to the heart rate effects of nicotine. Psychopharmacology 97: 529-534
63. Peters E R, Pickering A D, Hemsley D R (1994) 'Cognitive inhibition' and positive symptomatology in schizotypy. Br J Clin Psychol 33: 33-48
64. Pritchard W S (1991) The link between smoking and P: a serotonergic hypothesis. Person Individ Diff 12: 1187-1204
65. Provost S C, Woodward R (1991) Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 104: 536-540
66. Raine A (1991) The schizotypal personality questionnaire (SPQ): a scale for the measurement of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 17: 555-564
67. Raine A, Sheard C, Reynolds G P, Lencz T (1992) Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophr Res 7: 237-247
68. Robbins T W (1990) The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull 16: 391-402
69. Rochford J, Sen A P, Quirion R (1996) Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. J Pharmacol Exp Therapeut 277: 1267-1275
70. Siever L J (1994) Biologic factors in schizotypal personality disorders. Psych Scand 90: 45-50
71. Siever L J, Kalus O F, Keefe R S E (1993) The boundaries of schizophrenia. Psychiatr Clin North Am 16: 217-245
72. Solomon P R, Crider A, Winkelman J W, Turi A, Kamer R M, Kaplan L J (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16: 519-537
73. Stroop J R (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-662
74. Suter T W, Buzzi R, Woodson P P, Bättig K (1983) Psychophysiological correlates of conflict solving and cigarette smoking. Activ Nerv Sup 25: 261-272
75. Swerdlow N R, Filion D, Geyer M A, Braff D L (1995) 'Normal' personality correlates of sensorimotor, cognitive, and visuospatial gating. Biol Psychiatry 37: 286-299
76. Swerdlow N R, Braff D L, Hartston H, Perry W, Geyer M A (1996) Latent inhibition in schizophrenia. Schizophr Res 20: 91-103
77. Thornton J C, Dawe S, Lee C, Capstick C, Corr P J, Cotter P, Frangou S, Gray N S, Russell M A H, Gray J A (1996) Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology 127: 164-173
78. Tipper S P (1985) The negative priming effect: inhibitory effects of ignored primes. Quart J Exp Psychol 37A: 139-154
79. Tyrka A R, Cannon T D, Haslam N, Mednick S A, Schulsinger F, Schulsinger H, Parnas J (1995) The latent structure of schizotypy: I. Premorbid structure of a taxon of individuals at risk for schizophrenia-spectrum disorders. J Abnorm Psychol 104: 173-185
80. Vollema M G, Van den Bosch R J (1995) The multidimensionality of schizotypy. Schizophr Bull 21: 19-31
81. Warburton E C, Joseph M H, Feldon J, Weiner I, Gray J A (1994) Antagonism of amphetamine-induced disruption of LI in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114: 657-664
82. Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychol Bull 108: 442-461
83. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91: 248-253
84. Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88: 11-25
85. Weiner I, Lubow R E, Feldon J (1981) Chronic amphetamine and latent inhibition. Behav Brain Res 2: 285-286
86. Weiner I, Lubow R E, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83: 194-199
87. Weiner I, Feldon J, Katz Y (1987) Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26: 241-246
88. Weiner I, Lubow R E, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30: 871-878
89. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996) The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic clozapine. Biol Psychiatry 40: 834-843
90. Weiner I, Shadach E, Barkai R, Feldon J (1997) Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16: 42-50
91. Wesnes K, Warburton D M (1978) The effects of cigarette smoking and nicotine tablets upon human attention. In Thornton R E (ed.), Smoking behaviour, pp. 131-147. Churchill Livingstone, Edinburgh
92. Wesnes K, Warburton D M (1983) Smoking, nicotine and human performance. Pharmacol Ther 21: 189-208
93. Williams L M (1995) Further evidence for a multidimensional personality disposition to schizophrenia in terms of cognitive inhibition. Br J Clin Psychol 34: 193-213
94. Williams J H, Wellman N A, Geaney D P, Cowen P J, Feldon J, Rawlins J N P (1996) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry 40: 1135-1143
95. Williams J H, Wellman N A, Geaney D P, Feldon J, Cowen P J, Rawlins J N P (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133: 262-268